Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|
Income Statement | |||||
Total Revenue | 61.00K | 130.00K | 84.68M | 10.65M | 7.76M |
Gross Profit | 61.00K | 130.00K | 68.22M | -3.88M | 281.00K |
EBITDA | -200.64M | -226.76M | -166.65M | -199.94M | -207.64M |
Net Income | -342.99M | -234.63M | -4.75M | -285.50M | -198.53M |
Balance Sheet | |||||
Total Assets | 490.86M | 750.03M | 937.56M | 1.13B | 908.28M |
Cash, Cash Equivalents and Short-Term Investments | 370.53M | 546.22M | 640.15M | 614.79M | 612.62M |
Total Debt | 58.97M | 63.17M | 67.70M | 67.82M | 54.57M |
Total Liabilities | 108.03M | 95.08M | 104.31M | 197.62M | 189.84M |
Stockholders Equity | 382.82M | 654.95M | 833.25M | 929.79M | 718.44M |
Cash Flow | |||||
Free Cash Flow | -162.86M | -166.38M | -193.83M | -191.75M | -212.35M |
Operating Cash Flow | -162.39M | -163.69M | -169.56M | -126.25M | -160.87M |
Investing Cash Flow | 122.42M | 184.05M | -11.54M | -121.57M | -273.52M |
Financing Cash Flow | 1.33M | 1.74M | 10.63M | 401.24M | 476.79M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
60 Neutral | HK$16.77B | 6.05 | -6.36% | 3.69% | 11.62% | -23.89% | |
59 Neutral | $170.34M | ― | -71.20% | ― | -4.41% | -38.08% | |
57 Neutral | $297.40M | ― | -32.97% | ― | ― | ― | |
55 Neutral | $125.34M | ― | -24.73% | ― | -1.02% | -8.59% | |
53 Neutral | $266.79M | ― | 123.38% | ― | 10.49% | 47.31% | |
49 Neutral | $122.66M | ― | -49.23% | ― | 105.85% | 22.13% | |
39 Underperform | $150.43M | ― | -26.10% | ― | ― | 30.76% |
On July 24, 2025, Lyell Immunopharma entered into a Securities Purchase Agreement to raise up to $100 million through a private placement with institutional and accredited investors. The initial closing, expected around July 25, 2025, will generate approximately $50 million, with the potential for an additional $50 million upon achieving specific clinical or corporate milestones within a year. The proceeds will fund pivotal-stage clinical trials of LYL314 and support general corporate purposes, with expectations to sustain operations into mid-2027. This financial move positions Lyell to advance its clinical trials and potentially submit a Biologics License Application in 2027 for LYL314 in treating large B-cell lymphoma.
The most recent analyst rating on (LYEL) stock is a Hold with a $80.00 price target. To see the full list of analyst forecasts on Lyell Immunopharma stock, see the LYEL Stock Forecast page.
On June 17, 2025, Lyell Immunopharma announced new clinical data from its ongoing Phase 1/2 trial of LYL314, a CAR T-cell therapy for large B-cell lymphoma (LBCL). The trial showed promising results with high overall response rates and manageable safety profiles in both third- or later-line (3L+) and second-line (2L) settings. The company plans to initiate a randomized pivotal trial by early 2026 and has the manufacturing capacity to support clinical development and early commercial launch if approved.
The most recent analyst rating on (LYEL) stock is a Hold with a $80.00 price target. To see the full list of analyst forecasts on Lyell Immunopharma stock, see the LYEL Stock Forecast page.
On June 9, 2025, Lyell Immunopharma‘s Board of Directors expanded from seven to eight members, appointing Mark Bachleda, Pharm.D., M.B.A., as a Class I director. Dr. Bachleda will serve until the 2028 annual stockholders meeting, receiving compensation and equity grants as per the company’s policy, adjusted for a recent reverse stock split.
The most recent analyst rating on (LYEL) stock is a Hold with a $80.00 price target. To see the full list of analyst forecasts on Lyell Immunopharma stock, see the LYEL Stock Forecast page.
On May 27, 2025, Lyell Immunopharma announced a reverse stock split at a 1-for-20 ratio, authorized by its stockholders during the annual meeting on May 15, 2025. Effective May 30, 2025, this move will consolidate every 20 shares into one, adjusting stock options and equity plans proportionately, with trading on a split-adjusted basis starting June 2, 2025, on Nasdaq. This action aims to streamline the company’s stock structure without altering shareholders’ proportional ownership.
The most recent analyst rating on (LYEL) stock is a Hold with a $4.00 price target. To see the full list of analyst forecasts on Lyell Immunopharma stock, see the LYEL Stock Forecast page.
On May 15, 2025, Lyell Immunopharma held its annual meeting of stockholders virtually, with 71.9% of shares represented, constituting a quorum. Stockholders voted on four proposals, including the election of Catherine Friedman as a director, ratification of Ernst & Young LLP as auditors, approval of executive compensation, and potential reverse stock split amendments, all of which were passed.
The most recent analyst rating on (LYEL) stock is a Hold with a $4.00 price target. To see the full list of analyst forecasts on Lyell Immunopharma stock, see the LYEL Stock Forecast page.